Accelerated Pharma (Accelerated Pharma) Dividend Payout Ratio : 0.00 (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Dividend Payout Ratio?

Accelerated Pharma's dividend payout ratio for the months ended in Mar. 2017 was 0.00.

The historical rank and industry rank for Accelerated Pharma's Dividend Payout Ratio or its related term are showing as below:

ACCP's Dividend Payout Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.33
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-20), the Dividend Yield % of Accelerated Pharma is 0.00%.

Accelerated Pharma's Dividends per Share for the months ended in Mar. 2017 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Accelerated Pharma Dividend Payout Ratio Historical Data

The historical data trend for Accelerated Pharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Dividend Payout Ratio Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dividend Payout Ratio

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Dividend Payout Ratio	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Accelerated Pharma's Dividend Payout Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's Dividend Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Dividend Payout Ratio falls into.

Accelerated Pharma Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Accelerated Pharma's Dividend Payout Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2016 )	/	EPS without NRI (A: Dec. 2016 )
	=	0	/	-0.57
	=	N/A

Accelerated Pharma's Dividend Payout Ratio for the quarter that ended in Mar. 2017 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2017 )	/	EPS without NRI (Q: Mar. 2017 )
	=	0	/	-0.09
	=	N/A

Accelerated Pharma (NAS:ACCP) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Accelerated Pharma Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines